Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01RXW
|
|||
| Former ID |
DCL001250
|
|||
| Drug Name |
Vaniprevir
|
|||
| Synonyms |
Vaniprevir; UNII-CV3X74AO1H; MK-7009; MK7009; 923590-37-8; CV3X74AO1H; Vaniprevir [USAN:INN]; vanihep; 3su6; SCHEMBL3264200; BDBM103836; BCP09841; ZINC95627836; AKOS030527003; SB16734; DB11929; CS-0340; NCGC00485973-01; HY-10243; Cyclopropanecarboxamide, N-(((6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1-2)-lactone, (1R,2R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C38H55N5O9S
|
|||
| Canonical SMILES |
CCC1CC1(C(=O)NS(=O)(=O)C2CC2)NC(=O)C3CC4CN3C(=O)C(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
|
|||
| InChI |
1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1
|
|||
| InChIKey |
KUQWGLQLLVFLSM-ONAXAZCASA-N
|
|||
| CAS Number |
CAS 923590-37-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Merck (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.